)
)
2Seventy Bio Investor Relations Material
Latest events
Q3 2024
2Seventy Bio
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from 2Seventy Bio Inc
Access all reports
2Seventy Bio Inc. (NASDAQ: TSVT) is a biotechnology company specializing in cell and gene therapy with a focus on developing and commercializing treatments for cancer within the United States. The company's research and development efforts are centered on advancing a pipeline of chimeric antigen receptor-T cell (CAR-T) product candidates, including idecabtagene vicleucel (ide-cel or Abecma) and bb21217, aimed at treating multiple myeloma. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
TSVT
Country
🇺🇸 United States